A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf
.
Herceptin-Mediated Cardiotoxicity: Assessment by Cardiovascular Magnetic Resonance
2022
Cardiology Research and Practice
Herceptin (trastuzumab) is a recombinant, humanized, monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2) and is used in the treatment of HER2-positive breast and gastric cancers. However, it carries a risk of cardiotoxicity, manifesting as left ventricular (LV) systolic dysfunction, conventionally assessed for by transthoracic echocardiography. Clinical surveillance of cardiac function and discontinuation of trastuzumab at an early stage of LV systolic
doi:10.1155/2022/1910841
pmid:35265371
pmcid:PMC8898877
fatcat:xqhiu6hxlrhbvak4wv4efao5hy